Media

On November 17th (local time), at the press center of the 30th Conference of the Parties to the United Nations Framework Convention on Climate Change (COP30) held in Belém, Brazil, the Publicity and Education Center of the Ministry of Ecology and Environment, together with the China Champions for Climate Action, held the launch event of 2025 Beautiful China · Green Space Users Case Collection (hereinafter referred to as the "Case Collection") . Among the 40 selected cases, Yangtze River Pharmace

On November 5th, at the 50th International Convention on Quality Control Circles (ICQCC), Yangtze River Pharmaceutical Group (referred to as YRPG) stood out from nearly 600 participating projects worldwide with its fruitful achievements in quality management research. It won 5 gold medals and 1 silver medal in one fell swoop, setting a brilliant record for Chinese enterprises at this year’s "Quality Olympics".ICQCC is an influential international conference in the field of quality management, fe

October 28–31, 2025, Yangtze River Pharmaceutical Group Co., Ltd ( the Group) participated in CPHI(Chemical and Pharmaceutical International Exhibition) Worldwide in Frankfurt, Germany, conducting friendly and pleasant exchanges with representatives from pharmaceutical manufacturers around the world. The participating team focused on introducing the Group’s chemical drugs, traditional Chinese medicines, big health products and medical devices to global pharmaceutical companies at the exhibition.

On October 25, 2025, the Guangzhou Huirui factory, under Yangtze River Pharmaceutical Group (the Group), successfully completed the production of two batches of Parecoxib Sodium for Injection for the UK. The products are now ready to be shipped to the UK market. This smooth delivery is not only a strong testament to the efficient collaboration of the Group's international supply chain, but also a landmark breakthrough in the Group's strategic layout for the internationalization of high-e

At the Osaka World Expo in Japan, the “China Enterprises’ Outstanding Global ESG Practices Exchange Conference” was successfully held at the China Pavilion. Co-hosted by the Legal Affairs Center of China Council for the Promotion of International Trade , China International Chamber of Commerce and the United Nations Institute for Training and Research, the conference aims to promote the strategic transformation of Chinese enterprises from Going Global to Jointly Building, align with internationa

From September 6 to 10, 2025, the World Sleep 2025 Congress and 2025 Annual Meeting of the Asian Sleep Society (ASSM 2025) took place in Singapore. At the event, Yangtze River Pharmaceutical Group (the Group) unveiled the Phase III clinical trial results of Fazamorexant (research code: YZJ-1139), an innovative Class 1 anti-insomnia drug it developed. As an orexin dual receptor antagonist (DORA), the results were presented for the first time globally, with the study abstract displayed at the conf

On September 8, Xu Haoyu, Secretary of the Party Committee, Chairman of the Board, and President of the Group, was invited to visit the Embassy of the United Arab Emirates (UAE) in Beijing, where he held a cordial and friendly discussion with Hussein Bin Ibrahim Al Hammadi, UAE Ambassador to China. Both sides focused on the pharmaceutical and healthcare sector in the Middle East market, conducted exchanges on cooperation, reached a number of consensuses, and built a new bridge for cooperation to

Recently, Jiangsu Haici Bio-Pharmaceutical Co., Ltd. ("Haici Bio"), a subsidiary of Yangtze River Pharmaceutical Group, achieved a major milestone by passing the on-site inspection of Japan's PMDA with zero defects. This is the first time the Group's API sector has undergone an on-site audit by a foreign official authority, indicating its quality management system and production standards meet international levels, laying a solid foundation for its global strategic layout. The PMDA certi